Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
| 대상 질환 | Prostate Carcinoma |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Wake Forest University Health Sciences |
| 상태 | 조기 종료 |
| 참여자 수 | 46 명 |
| 중재(약물) | Laboratory Biomarker Analysis, Propranolol Hydrochloride, Questionnaire Administration, Survey Administration |
| 시작일 | 2019년 1월 15일 |
| 완료일 | 2021년 6월 15일 |
| 결과 공개일 | 2025년 2월 17일 |
요약
This randomized pilot clinical trial studies how well propranolol hydrochloride works in treating patients with prostate cancer who are undergoing surgery. When stressed, the body makes a molecule that may prevent tumor cells from dying, and propranolol hydrochloride may affect the signals in cells that cause tumor cells survival and death.
Mean Level of CREB Phosphorylation
| Group I (Propranolol Hydrochloride) | 1.34 ± .33 West blot band intensity,arbitrary units |
|---|---|
| Group II (no Treatment) | 1.43 ± .46 West blot band intensity,arbitrary units |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate — Aragon Pharmaceuticals, Inc.
- Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced P — National Cancer Institute (NCI)
- M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castr — National Cancer Institute (NCI)
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abirate — Janssen Research & Development, LLC
- Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Ola — National Cancer Institute (NCI)
- A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Pr — Janssen Research & Development, LLC